“In Q1, we showed that IMM-1-104 can drive exceptional efficacy for patients with pancreatic cancer, including a third-line monotherapy patient with over 13 months progression-free survival, a second-line monotherapy patient with a confirmed partial response, and a first-line combination therapy patient with a confirmed complete response. These outcomes are particularly striking given the excellent tolerability observed with IMM-1-104. In January, we reported encouraging overall response rates and disease control rates for IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer. We are excited to share survival data in a larger group of patients in the coming weeks,” said Ben Zeskind, co-founder and CEO of Immuneering (IMRX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Promising Potential: Buy Rating Backed by Strategic Expansion and Data Generation
- Immuneering Corp. Reports Promising Cancer Trial Results
- Immuneering management to meet with Oppenheimer
- Immuneering’s Strategic Advancements and Financial Strength Bolster Buy Rating
- Immuneering reports Q4 EPS (58c), consensus (44c)